Combination Chemotherapy Followed By Stem Cell Transplant in Treating Young Patients With Progressive or Relapsed Anaplastic Large Cell Lymphoma

NCT00317408 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 96

Last updated 2015-09-25

No results posted yet for this study

Summary

RATIONALE: Giving combination chemotherapy and total-body irradiation before a peripheral stem cell transplant that uses the patient's or a donor's stem cells, helps stop both the growth of cancer cells and the patient's immune system from rejecting the stem cells. When the stem cells are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Giving combination chemotherapy and total-body irradiation followed by a stem cell transplant may be an effective treatment for anaplastic large cell lymphoma.

PURPOSE: This clinical trial is studying how well combination chemotherapy followed by stem cell transplant works in treating young patients with progressive or relapsed anaplastic large cell lymphoma.

Conditions

Interventions

BIOLOGICAL

anti-thymocyte globulin

DRUG

busulfan

DRUG

carmustine

DRUG

cyclosporine

DRUG

cytarabine

DRUG

etoposide phosphate

DRUG

idarubicin

DRUG

ifosfamide

DRUG

leucovorin calcium

DRUG

lomustine

DRUG

melphalan

DRUG

methotrexate

DRUG

mitoxantrone hydrochloride

DRUG

prednisolone

DRUG

thiotepa

DRUG

vinblastine sulfate

DRUG

vindesine

PROCEDURE

allogeneic hematopoietic stem cell transplantation

PROCEDURE

autologous hematopoietic stem cell transplantation

PROCEDURE

peripheral blood stem cell transplantation

RADIATION

total-body irradiation

Sponsors & Collaborators

  • European Inter-group Cooperation on Childhood and Adolescent Non Hodgkin Lymphoma

    lead OTHER

Principal Investigators

  • Alfred Reiter, MD · University Hospital Erlangen

  • Denise Williams, MD · Cambridge University Hospitals NHS Foundation Trust

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT

Eligibility

Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-04-30
Primary Completion
2014-02-28

Countries

  • Austria
  • Belgium
  • Czechia
  • France
  • Germany
  • Ireland
  • Italy
  • Netherlands
  • Poland
  • Sweden
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00317408 on ClinicalTrials.gov